QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:CALA

Calithera Biosciences Stock Forecast, Price & News

$0.80
+0.03 (+3.91%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.76
$0.83
50-Day Range
$0.77
$2.40
52-Week Range
$0.76
$6.19
Volume
749,977 shs
Average Volume
1.30 million shs
Market Capitalization
$59.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.57
30 days | 90 days | 365 days | Advanced Chart
Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences logo

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Headlines

Calithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Update
November 29, 2021 |  americanbankingnews.com
Calithera Biosciences Insider Trades $170K In Company Stock
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
93
Year Founded
N/A

Sales & Book Value

Annual Sales
$22.25 million
Book Value
$1.45 per share

Profitability

Net Income
$-90.14 million
Pretax Margin
-701.99%

Debt

Price-To-Earnings

Miscellaneous

Free Float
66,235,000
Market Cap
$59.79 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

156th out of 1,391 stocks

Pharmaceutical Preparations Industry

66th out of 669 stocks

Analyst Opinion: 3.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Calithera Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares.
View analyst ratings for Calithera Biosciences
or view top-rated stocks.

How has Calithera Biosciences' stock price been impacted by Coronavirus?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CALA stock has decreased by 84.7% and is now trading at $0.7980.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a decline in short interest in November. As of November 15th, there was short interest totaling 900,900 shares, a decline of 58.9% from the October 31st total of 2,190,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.3% of the shares of the company are sold short.
View Calithera Biosciences' Short Interest
.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Calithera Biosciences
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.08. During the same period in the previous year, the company earned ($0.32) EPS.
View Calithera Biosciences' earnings history
.

What price target have analysts set for CALA?

3 brokerages have issued 12-month target prices for Calithera Biosciences' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Calithera Biosciences' share price to reach $3.67 in the next year. This suggests a possible upside of 359.5% from the stock's current price.
View analysts' price targets for Calithera Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (14.31%), BVF Inc. IL (9.95%), BlackRock Inc. (3.42%), Dimensional Fund Advisors LP (1.36%), Geode Capital Management LLC (1.09%) and Assenagon Asset Management S.A. (1.02%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong and Susan Molineaux.
View institutional ownership trends for Calithera Biosciences
.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, BlackRock Inc., and Goldman Sachs Group Inc..
View insider buying and selling activity for Calithera Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Assenagon Asset Management S.A., Primecap Management Co. CA, TSP Capital Management Group LLC, Two Sigma Investments LP, BVF Inc. IL, Franklin Resources Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Calithera Biosciences
or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.80.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $59.79 million and generates $22.25 million in revenue each year. The biotechnology company earns $-90.14 million in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 93 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

Where are Calithera Biosciences' headquarters?

Calithera Biosciences is headquartered at 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.